Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

BioSphere Medical, Inc. - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.

14 May 2010

Merit Medical Systems to acquire BioSphere Medical

Merit Medical Systems, Inc. today announced that it has signed a definitive merger agreement to acquire BioSphere Medical, Inc. in an all cash transaction valued at approximately $96 million, inclusive of all common equity and Series A Preferred preferences.

14 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.

30 Apr 2010

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives - experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

28 Apr 2010

Noncompetitive ''win-win'' relationship between gynecologist and radiologist benefits patients

Journal of Minimally Invasive Gynecology (JMIG) has published a study in its March/April issue which concluded that establishing a referral relationship with an interventional radiologist for comprehensive uterine myoma (fibroid) treatment supports a trusting, collaborative, long-term, noncompetitive ''win-win'' relationship between the gynecologist and radiologist.

13 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Request for lift of full clinical hold on Proellex program

Repros Therapeutics Inc. today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity.

5 Apr 2010

Cook Medical to feature its Goldstein SonoBiopsy Catheter at 2010 AIUM convention

With over 10 million women in the U.S. suffering from endometrial disorders like abnormal uterine bleeding or uterine fibroids, the 2010 American Institute of Ultrasound Medicine convention will feature specialized programs and product showcases highlighting imaging solutions available to better diagnose these conditions.

26 Mar 2010

Study reveals comparable fertility rates between UFE and surgical myomectomy

Uterine fibroid embolization, a minimally invasive interventional radiology procedure that blocks blood supply to treat painful uterine fibroids, has a comparable fertility rate to myomectomy, the surgical removal of uterine fibroids, for women who want to conceive, according to the first study on the subject released at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Uterine fibroids: Promising new minimally invasive treatment using high-energy ultrasound waves

There's a new interventional radiology tool showing promise in the treatment of uterine fibroids: magnetic resonance-guided focused ultrasound (MRgFUS), a minimally invasive treatment that uses high-energy ultrasound waves to generate heat at a specific point to destroy uterine fibroid tissue and relieve symptoms.

16 Mar 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

BioSphere Medical reports fourth-quarter and full-year 2009 results

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported financial results for the three and 12 months ended December 31, 2009.

10 Feb 2010

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Elbit Imaging ("Elbit Imaging" "Company") announced today that it intends to restructure its bio-tech and medical holdings (InSightec - 60%, and Gamida Cell - 28%; both on a fully diluted basis) under a wholly-owned Elbit Imaging subsidiary and to offer shares of such subsidiary in a public offering on the Tel Aviv Stock Exchange ("IPO").

2 Feb 2010

Halt Medical commences enrollment in uterine fibroid study

The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.

2 Feb 2010

Japan's MHLW approves InSightec's ExAblate MRgFUS system

InSightec Ltd. announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the company's ExAblate(R) MR-guided Focused Ultrasound (MRgFUS) system for the treatment of women with uterine fibroids.

18 Jan 2010

IntegraMed America plans to open new vein clinic in Columbia, Maryland

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced plans to open a new vein clinic in Columbia, Maryland in mid 2010.

9 Jan 2010

Montefiore Medical Center first to perform minimally invasive procedure on uterine fibroids

Montefiore Medical Center recently became the only hospital on the East Coast to conduct the Radio Frequency Ablation procedure to shrink uterine fibroids in women 30 years and older.

6 Jan 2010

Findings suggest abuse is a risk factor for chronic headache

Researchers from the American Headache Society's Women's Issues Section Research Consortium found that incidence of childhood maltreatment, especially emotional abuse and neglect, are prevalent in migraine patients.

5 Jan 2010

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

Merit Medical Systems to acquire BioSphere Medical

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

FDA issues advisory on prostate cancer drugs

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

Noncompetitive ''win-win'' relationship between gynecologist and radiologist benefits patients

StockPreacher.com releases investment report on Repros Therapeutics

Request for lift of full clinical hold on Proellex program

Cook Medical to feature its Goldstein SonoBiopsy Catheter at 2010 AIUM convention

Study reveals comparable fertility rates between UFE and surgical myomectomy

Uterine fibroids: Promising new minimally invasive treatment using high-energy ultrasound waves

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

BioSphere Medical reports fourth-quarter and full-year 2009 results

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Halt Medical commences enrollment in uterine fibroid study

Japan's MHLW approves InSightec's ExAblate MRgFUS system

IntegraMed America plans to open new vein clinic in Columbia, Maryland

Montefiore Medical Center first to perform minimally invasive procedure on uterine fibroids

Findings suggest abuse is a risk factor for chronic headache

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in